$0.45
1.86% yesterday
Nasdaq, Nov 15, 10:20 pm CET
ISIN
US81728A1088
Symbol
SNSE
Sector
Industry

Sensei Biotherapeutics Inc Stock price

$0.45
-0.01 2.47% 1M
-1.04 69.56% 6M
-0.24 34.47% YTD
-0.15 25.02% 1Y
-9.42 95.41% 3Y
-18.55 97.61% 5Y
-18.55 97.61% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.01 1.86%
ISIN
US81728A1088
Symbol
SNSE
Sector
Industry

Key metrics

Market capitalization $11.62m
Enterprise Value $-35.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.46
P/B ratio (TTM) P/B ratio 0.22
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-32.48m
Cash position $52.29m
EPS (TTM) EPS $-1.19
P/E forward negative
Short interest 1.16%
Show more

Is Sensei Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Sensei Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Sensei Biotherapeutics Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Sensei Biotherapeutics Inc forecast:

Buy
100%

Financial data from Sensei Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
-0.55 -0.55
71% 71%
-
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 19 19
6% 6%
-
- -
-
-
- Depreciation and Amortization 0.55 0.55
71% 71%
-
EBIT (Operating Income) EBIT -32 -32
20% 20%
-
Net Profit -30 -30
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Sensei Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sensei Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
one day ago
- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery an...
Neutral
GlobeNewsWire
18 days ago
BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences.
Neutral
GlobeNewsWire
2 months ago
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-1...
More Sensei Biotherapeutics Inc News

Company Profile

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Head office United States
CEO John Celebi
Employees 27
Founded 1999
Website senseibio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today